Novel target antigens for dendritic cell-based immunotherapy against ovarian cancer
- 1 February 2002
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 2 (1) , 97-105
- https://doi.org/10.1586/14737140.2.1.97
Abstract
Identification of tumor-specific target antigens has been a major hurdle for the treatment of malignant disease by vaccination or immunotherapy. A second challenge has been the induction of therapeutically effective immune responses to these 'self' antigens. The recent recognition of dendritic cells as powerful antigen-presenting cells capable of inducing primary T-cell responses in vitro and in vivo--in combination with identification of tumor-specific antigens--has generated widespread interest in dendritic cell-based immunotherapy against a wide variety of tumors. In this review, a series of recently identified novel ovarian tumor antigens is discussed, and the potential for therapeutic dendritic cell vaccination targeted against these antigens is assessed.Keywords
This publication has 28 references indexed in Scilit:
- Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybridsNature Medicine, 2000
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- A novel tumor-associated antigen expressed in human uterine and ovarian carcinomasCancer, 1996
- THE IMMUNOTHERAPY OF SOLID CANCERS BASED ON CLONING THE GENES ENCODING TUMOR-REJECTION ANTIGENSAnnual Review of Medicine, 1996
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cellsNature Medicine, 1996
- Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.The Journal of Experimental Medicine, 1996
- Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.Proceedings of the National Academy of Sciences, 1989